

CLINICAL PRACTICE GUIDELINES

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines[†]

M. Aapro¹, Y. Beguin^{2,3}, C. Bokemeyer⁴, M. Dicato⁵, P. Gascón⁶, J. Glaspy⁷, A. Hofmann⁸, H. Link⁹, T. Littlewood¹⁰, H. Ludwig¹¹, A. Österborg¹², P. Pronzato¹³, V. Santini¹⁴, D. Schrijvers¹⁵, R. Stauder¹⁶, K. Jordan¹⁷ & J. Herrstedt^{18,19}, on behalf of the ESMO Guidelines Committee*

¹Genolier Cancer Centre, Clinique de Genolier, Genolier, Switzerland; ²University of Liège, Liège; ³CHU of Liège, Liège, Belgium; ⁴Department of Oncology, Hematology and BMT with Section Pneumology, University of Hamburg, Hamburg, Germany; ⁵Hématologie-Oncologie, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg; ⁶Department of Haematology-Oncology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain; ⁷Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA; ⁸Medical Society for Blood Management, Laxenburg, Austria; ⁹Klinik für Innere Medizin I, Westpfalz-Klinikum, Kaiserslautern, Germany; ¹⁰Department of Haematology, John Radcliffe Hospital, Oxford, UK; ¹¹Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; ¹²Karolinska Institute and Karolinska Hospital, Stockholm, Sweden; ¹³Medica Oncology, IRCCS Asiana Pedaliter Universitaria San Martino – IST, Istituto Nazionale per la Ricercars sol Cancere, Genova; ¹⁴Department of Experimental and Clinical Medicine, Haematology, University of Florence, Florence, Italy; ¹⁵Department of Medical Oncology, Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium; ¹⁶Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck, Austria; ¹⁷Department of Medicine V, University of Heidelberg, Heidelberg, Germany; ¹⁸Department of Oncology, Zealand University Hospital Roskilde, Roskilde; ¹⁹University of Copenhagen, Copenhagen, Denmark

*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org

[†]Approved by the ESMO Guidelines Committee: October 2017.

Anaemia and iron deficiency (ID) are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents [1–3]. Frequently, anaemia is associated with fatigue, impaired physical function and reduced quality of life (QoL) [4–7]. Consequences of anaemia may include impaired response to cancer treatment and reduced overall survival (OS), even though a causal direct relationship has not yet been established [8, 9].

These new ESMO Clinical Practice Guidelines provide tools to evaluate anaemia, also in patients with myelodysplastic syndromes (MDS), and include recommendations on how to safely manage chemotherapy-induced anaemia (CIA) with erythropoiesis-stimulating agents (ESAs), iron preparations for intravenous (i.v.) or oral administration, red blood cell (RBC) transfusions and combinations of these treatments [10–13]. The major aims of anaemia management are the reduction or resolution of anaemia symptoms, particularly fatigue, and an improved QoL with the minimum invasive treatment that corrects the underlying causes and proves to be safe. Underlying causes of anaemia, mainly impaired erythropoietic activity and disturbed iron homeostasis, can be consequences of increased release of inflammatory cytokines due to the underlying cancer and/or toxicity of cancer therapy. Furthermore, vitamin B12 and folate deficiency are relatively rare causes of anaemia in cancer patients.

Notably, also more than half of patients with MDS are characterised by a haemoglobin (Hb) level < 10 g/dL, resulting in

reduced functional capacities and health-related QoL, and > 80% of these patients require RBC transfusions [14–17]. However, ESAs were not approved by the European Medicines Agency (EMA) for use in MDS patients despite being used effectively in MDS for at least 20 years; their activity has been demonstrated in numerous clinical trials, with published evidence existing for more than 2500 ESA-treated MDS patients [14]. Randomised clinical trials are ongoing.

Since the publication of the European Society of Medical Oncology (ESMO) anaemia Clinical Practice Guidelines in 2010 [18] and the last review of the European Organisation for Research and Treatment of Cancer (EORTC) anaemia treatment guidelines in 2006 [19] (last update in 2007 [20]), clinical experience with ESAs and iron preparations and the understanding of iron homeostasis have markedly increased [10, 21]. Furthermore, specific safety aspects of the different treatment options have been addressed by several analyses and reviews in recent years, although data on the use of blood transfusions in cancer patients are sparse. Therefore, new ESMO guidelines for the diagnosis and treatment of anaemia and ID in cancer patients were deemed necessary. In addition, these guidelines include aspects related to anaemia management in patients with MDS and update the most recent ESMO and European LeukemiaNet (ELN) treatment guidelines for MDS [15, 22].

Questions addressed by these guidelines and respective recommendations including levels of evidence and grades of recommendations [23] are summarised in Table 1 for the management

Table 1. Managing anaemia and ID in patients with solid tumours or haematological malignancies**When should ESA treatment be considered?**

Treatment of anaemia with an ESA should be considered in patients under ChT after correction of ID and other underlying causes other than the cancer or its treatment [I, A].

Which patients should receive ESA therapy?

ESA therapy is recommended in patients with symptomatic anaemia who receive ChT [I, A] or combined RT-ChT [II, B] and present with an Hb level < 10 g/dL, as well as patients with asymptomatic anaemia who receive ChT and present with an Hb level < 8 g/dL.

Should patients who do not receive ChT treatment be treated with an ESA?

ESA treatment is not recommended in patients who are not on ChT [I, A].

What is the Hb target range for treatment with an ESA?

The Hb target is a stable level of ~ 12 g/dL without RBC transfusions [I, A].

At what doses should ESAs be given?

Dosing should follow the approved labels of the individual products; the currently recommended dosage is approximately 450 IU/week/kg body weight for epoetins alpha, beta and zeta; 6.75 µg/kg body weight every 3 weeks or 2.25 µg/kg body weight weekly for darbepoetin alpha; and 20 000 IU once weekly for epoetin theta [I, A].

Should ESA doses be increased or ESA preparations changed in patients not responding within 4–8 weeks?

Except for patients receiving epoetin theta (given at an intentionally low starting dose), ESA dose escalations and changes from one ESA to another in patients not responding within 4–8 weeks are not recommended. Patients who do not show evidence of at least an initial Hb response at this time should stop ESA therapy. The epoetin theta dose may be doubled after 4 weeks if Hb has not increased by at least 1 g/dL, unless functional ID is detected (see next recommendation) [I, A].

Which patients should receive iron therapy?

Patients receiving ongoing ChT who present with anaemia (Hb ≤ 11 g/dL or Hb decrease ≥ 2 g/dL from a baseline level ≤ 12 g/dL) and absolute ID (serum ferritin < 100 ng/mL) should receive iron treatment with an i.v. iron preparation to correct ID. If ESA treatment is considered, iron treatment should be given before the initiation of and/or during ESA therapy in the case of functional ID (TSAT < 20% and serum ferritin > 100 ng/mL) [I, A].

Should patients receive i.v. iron therapy without an ESA?

i.v. iron without additional anaemia therapy may be considered in individual patients with functional ID (TSAT < 20% and serum ferritin > 100 ng/mL) [III, C].

Should patients who are not on ChT receive iron therapy?

Iron treatment should be limited to patients on ChT. In patients receiving cardiotoxic ChT, i.v. iron should either be given before or after (not on the same day) administration of ChT or at the end of a treatment cycle [III, C].

At what doses should i.v. iron be given?

Patients with confirmed functional ID should receive a dose of 1000 mg iron given as single dose or multiple doses according to the label of available i.v. iron formulations. Patients with confirmed absolute ID should receive i.v. iron doses according to the approved labels of available products until correction of ID [I, A].

Which patients should be considered for RBC transfusions?

In patients with Hb < 7–8 g/dL and/or severe anaemia-related symptoms (even at higher Hb levels) and the need for immediate Hb and symptom improvement, the administration of RBC transfusions without delay is justified [II, B].

ChT, chemotherapy; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; ID, iron deficiency; i.v., intravenous; RBC, red blood cell; RT, radiotherapy; TSAT, transferrin saturation.

of anaemia and ID in patients with solid tumours or haematological malignancies and in Table 2 for the management of MDS. These recommendations are further illustrated in treatment algorithms (Figures 1 and 2). Discussions of specific aspects underlying the recommendations and related to the different treatment options are summarised in this article.

Anaemia management in patient populations with solid tumours or haematological malignancies

ESAs

ESAs have been shown to increase Hb levels and to reduce the need for RBC transfusions in cancer patients receiving chemotherapy

[24–27] and are approved for the treatment of CIA since 1993 [28]. Furthermore, a meta-analysis of 23 studies that reported QoL results and included 5584 patients showed a statistically significant difference between patients treated with ESAs and controls when combining QoL parameters and fatigue-related symptoms well as anaemia-related symptoms [29] (Table 3). However, the authors considered this finding to be not clinically important. Conversely, experience with patients responding to therapy and a recently published meta-analysis of 37 randomised, controlled trials with 10 581 patients suggest a small but clinically important improvement in anaemia-related symptoms [30].

Since early dose finding studies with epoetin beta did not show a difference in Hb response to 5000 and 10 000 IU/day (corresponding to 500 and 1000 IU/kg/week in a 70 kg individual) [31], and since there is not a single study on dose escalations showing a benefit, dose escalations in patients who do not respond within 4–8 weeks are not recommended (except for epoetin theta's

Table 2. Managing anaemia in patients with MDS**When should ESA treatment be considered?^a**

Treatment of anaemia with an ESA should be considered in MDS patients with symptomatic anaemia, Hb < 10 g/dL, low to intermediate-1 risk (IPSS) or very low to intermediate risk (IPSS-R), less than two RBC transfusions per month and/or serum EPO < 500 IU/L [I, A].

At what doses should ESAs be given?

ESAs should be given as fixed-dose, weekly, subcutaneous treatment at an initial dose in the range of 30 000–80 000 IU recombinant human EPO (epoetin theta starting dose is 20 000 IU) or up to 300 µg darbepoetin alpha [I, A].

How should MDS patients who are not responding to ESA treatment be treated?

In patients not responding to ESA treatment after 8–12 weeks, G-CSF should be added at ~ 300 µg/week, given in 2–3 doses. RBC transfusions or investigational medicinal products should be considered as second-line treatment in patients without a 5q deletion, and lenalidomide in patients who acquired a 5q deletion [I, A].

How should transfusion-dependent, anaemic MDS patients be treated?

Patients who require 2 or more RBC transfusions per month should be considered for treatment with an investigational agent or supportive care with RBC transfusions if they have no 5q deletion, or for lenalidomide if they have a 5q deletion [I, A].

^aESAs are not all EMA-approved for use in patients with MDS. Epoetin alpha is indicated by the EMA for the treatment of symptomatic anaemia (haemoglobin concentration of ≤ 10 g/dL) in adults with low or intermediate-1 risk primary MDS who have low serum EPO (<200 IU/mL).

EMA, European Medicines Agency; EPO, erythropoietin; ESA, erythropoiesis-stimulating agent; G-CSF, granulocyte colony-stimulating factor; Hb, haemoglobin; IPSS, International Prognostic Scoring System; IPSS-R, revised International Prognostic Scoring System; MDS, myelodysplastic syndrome; RBC, red blood cell.

low starting dose to be doubled after 4 weeks if Hb response is < 1 g/dL). Instead, ESA treatment should be stopped at this time point if there is no emerging sign of Hb response. There is no evidence of differing efficacy among ESAs (Table 4) and no recommendation can be made to change from one product to another in the case of an insufficient response. Because of possible safety issues, we continue to recommend that products should not be used interchangeably without adequate traceability and without notifying the treating physician [V, C].

Are ESAs linked to mortality and tumour progression?

In the late 2000s, the safety of ESAs was discussed when meta-analyses suggested that ESA treatment may affect mortality in cancer patients [32, 33], particularly if target Hb levels exceeded 12 g/dL [34–38]. Consequently, the recommended Hb target range for ESA treatment is 10–12 g/dL, and an Hb rise of > 2 g/dL over a 4-week period should be avoided. In 2014, a study in anaemic patients with metastatic breast cancer suggested that addition of erythropoietin (EPO) to standard of care with a target Hb > 12 g/dL did not meet the non-inferiority criteria for progression-free survival (PFS) versus standard of care alone [39]. However, the late separation of the PFS and OS curves can hardly be explained by a few weeks of EPO exposure. Notably, the most recent Cochrane review included subgroup analyses and showed statistically significant on-study mortality in patients with baseline Hb > 12 g/dL but not for Hb categories Hb < 10 g/dL and Hb = 10–12 g/dL that correspond to the currently approved cut-off for initiation and the target Hb range of ESA therapy [29]. When excluding one study with a target Hb range above the labelled guidance (BEST, target Hb = 12–14 g/dL [36]), the effect lost statistical significance [odds ratio; 95% confidence interval (CI): 1.09 (0.97–1.23)]. Data from large studies [40–42] and other meta-analyses [43–47] that have been reported since the label change did not indicate an effect of ESAs on risk of disease progression. A retrospective analysis of 47 342 chemotherapy-treated patients from the SEER-Medicare database (years 1991–2002, including 12 522 ESA-treated patients) showed

similar OS with or without ESA [48]. In November 2014, these data led the National Institute for Care and Health Excellence (NICE) in the UK to indicate that ESAs (epoetin alpha, beta, theta and zeta and darbepoetin alpha) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are receiving chemotherapy. If different ESAs are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used [49]. Overall, there is currently no clinical evidence (neither single studies nor meta-analyses) indicating an effect of ESAs on stimulating disease progression or relapse when used within label and following recommendations for the treatment of CIA [I, A] [29].

EPO receptor and tumour growth

Some reports suggested a potential role of the EPO receptor (EpoR) on tumour cells in tumour progression [50–52], yet there has been a controversial discussion about whether the tests for EpoR expression were specific enough [53] and about whether the functionality of detected EpoR (e.g. STAT5 activation [54]) was checked sufficiently [55–58]. In particular, the first publications suggesting EpoR expression in cancer cell lines used a polyclonal antibody [53], whereas more recent publications used a monoclonal (more specific) antibody against EpoR and failed to show such a receptor [57, 59]. Results showing that EPO may antagonise anti-HER2 therapy in breast cancer via Jak2-mediated signalling [60] suggest further investigation of this pathway. In recent *in vitro* studies, EpoR knockdown decreased proliferation of different tumour cell lines [61, 62], yet many tumour cell lines and primary renal cancer cells express constitutively phosphorylated (active) EpoR [63]. In animal tumour models, EPO did not enhance proliferation of tumour cell lines or affect mortality [52, 64].

ESAs and risk and prophylaxis (prevention) of thromboembolic events

Venous thromboembolic events (VTEs) are a known risk of ESA use in cancer patients [45], and the risk of a VTE is increased




Figure 1. Management of chemotherapy-induced anaemia in patients with solid or haematological malignancies.

^aOther parameters for impaired iron status: % hypochromic cells (%HYPO) > 5% and Hb content of reticulocytes (ChR) < 28 pg.

^bi.v. iron given as a single dose of 1000 mg iron or an equivalent total dose in several infusions as feasible with available i.v. iron formulations.

Oral iron to be considered only for patients with ferritin < 30 ng/mL and non-inflammatory conditions [CRP < 5 mg/L].

^cESA dosing should follow approved labels (i.e. ~450 IU/week/kg body weight for epoetins alpha, beta and zeta; 6.75 µg/kg body weight every 3 weeks or 2.25 µg/kg body weight weekly for darbepoetin alpha; 20 000 IU once weekly for epoetin theta which may be doubled after 4 weeks upon insufficient response). ESA dose escalations or a change to another ESA in patients who do not respond within 4–8 weeks are not recommended; ESA should be stopped in this case.

√, normal; CIA, chemotherapy-induced anaemia; CRP, C-reactive protein; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; ID, iron deficiency; i.v., intravenous; RBC, red blood cell; SF, serum ferritin; TSAT, transferrin saturation.

1.5-fold. The most important risk factors of a VTE are high haematocrit, older age, prolonged immobilisation, malignant disease, major surgery, multiple trauma, a previous VTE and chronic heart failure [43]. In addition, tumour types (e.g. pancreatic cancer) and treatment regimens (e.g. treatment with ESAs and/or immunomodulatory drugs in multiple myeloma) are associated with an increased risk of VTE [65, 66]. Clinical evidence on whether ESA treatment further increases the risk of VTEs when added to immunomodulatory treatments lenalidomide or thalidomide in patients with multiple myeloma is not

conclusive and may depend on the treatments used or the study design [67, 68]. In the absence of prospective randomised studies showing that antithrombotic therapy reduces the risk of VTEs in ESA-treated patients, prophylactic antithrombotic treatment is not recommended and the ESMO guidelines on VTEs should be followed [69]. Other guidelines in the field are issued by the National Comprehensive Cancer Network (NCCN) [70] and the American Society of Clinical Oncology (ASCO) [71]. Notably, VTEs may be in part associated with thrombocytosis, which correlates with ID that can occur due to the rapid consumption of available iron by




Figure 2. Management of anaemia in patients with very low to intermediate-risk MDS.

^aESA-treated patients who are iron deficient and transfusion independent may be considered for i.v. iron treatment.

EPO, erythropoietin; ESA, erythropoiesis-stimulating agent; G-CSF, granulocyte colony-stimulating factor; Hb, haemoglobin; IPSS, International Prognostic Scoring System; IPSS-R, revised International Prognostic Scoring System; i.v., intravenous; MDS, myelodysplastic syndrome; RBC, red blood cell; SF, serum ferritin; TSAT, transferrin saturation.

Adapted from [22].

the increased RBC synthesis after ESA treatment, but this remains to be further investigated [72, 73]. Overall, individual risks and harms should be balanced and discussed with the patient [V].

ID in patients with solid or haematological malignancies

ID is defined by insufficient iron availability for cellular functions, the most prominent being haem synthesis for erythropoiesis [74]. Absolute ID refers to depleted iron stores, whereas functional ID reflects insufficient availability of iron despite filled iron stores; this may be due to either iron sequestration in iron stores or increased iron needs during erythropoietic therapy [10, 75, 76]. In cancer patients, absolute ID is due mainly to bleeding, while other causes such as insufficient intestinal iron resorption,

e.g. due to poor nutrition, are usually of minor importance. Most importantly, iron homeostasis in cancer patients is often impaired via the release of proinflammatory cytokines and upregulation of hepcidin, the main regulator of iron uptake and release [76]. Increased hepcidin levels result in insufficient iron supply and functional ID due to internalisation of ferroportin, the most important transmembrane channel for the export of iron from enterocytes and macrophages into the circulation.

In 2006, the EORTC recommended iron treatment for the correction of ID before the initiation of ESA therapy [19] and recommended the use i.v. iron in patients with absolute or functional ID in the 2007 guideline update [20]. However, no details on iron status assessment or iron dosing were given due to limited evidence at that time.

Table 3. Benefit-risk profiles of treatments for anaemia and ID in cancer patients

	Benefits	Risks or limitations
ESAs	<ul style="list-style-type: none"> Reduction of RBC transfusions Improvement in anaemia-related symptoms 	<ul style="list-style-type: none"> Increase in thrombotic events PRCA in rare cases^a Increased mortality in patients receiving no cancer therapy or only RT Only effective in 60% of patients Induction of functional ID and decreasing response over time
i.v. iron ^b	<ul style="list-style-type: none"> Correction of ID anaemia Reduction of RBC transfusions Increase response to ESAs 	<ul style="list-style-type: none"> Long-term safety in oncology not yet fully established
RBC transfusions	<ul style="list-style-type: none"> Immediate increase of Hb and haematocrit levels in 100% Rapid improvement in anaemia-related symptoms 	<ul style="list-style-type: none"> Increase in thrombotic events Transfusion reactions and circulatory overload Transmission of known/unknown pathogens Possibly decreased survival in certain types of cancer treated by surgery Increased risk of infections due to immunosuppression

^aDocumented only in non-cancer chronic kidney disease patients.

^bOral iron to be considered only for patients with both absolute ID (ferritin < 100 ng/mL) and non-inflammatory conditions (CRP < 5 mg/L).

CRP, C-reactive protein; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; ID, iron deficiency; i.v., intravenous; PRCA, pure red cell aplasia; RBC, red blood cell; RT, radiotherapy.

Table 4. Approved ESAs and i.v. iron compounds and their approved dosing in patients with solid tumours and haematological malignancies^{a,b}

ESAs	
Epoetin alpha	450 IU/kg subcutaneously once weekly or 150 IU/kg subcutaneously 3 times per week
Epoetin beta	30 000 IU subcutaneously (i.e. ~ 450 IU/kg body weight in a 70 kg patient) given once weekly or divided over 3–7 times per week
Epoetin theta	20 000 IU subcutaneously independent of body weight given once weekly, dose may be doubled after 4 weeks if Hb has not increased by at least 1 g/dL
Epoetin zeta	450 IU/kg subcutaneously once weekly, or 150 IU/kg subcutaneously 3 times per week
Darbepoetin alpha	500 µg (6.75 µg/kg body weight) subcutaneously given once every 3 weeks or 2.25 µg/kg body weight subcutaneously once weekly
i.v. iron ^c	
Ferric gluconate	Maximum infusion dose: 125 mg iron Minimum infusion time: 60 min
Iron sucrose	Maximum infusion dose: 200–500 mg iron Minimum infusion time: 30–210 min
Iron dextran ^d	Maximum infusion dose: depends on exact iron dextran type; refer to label. Minimum infusion time: 240–360 min
Iron isomaltoside	Maximum infusion dose: 20 mg/kg body weight (up to 1000 mg iron ^e) Minimum infusion time: 15 min ^f
Ferric carboxymaltose	Maximum infusion dose: 20 mg/kg body weight (up to 1000 mg iron per week) Minimum infusion time: 15 min

^aEpoetin alpha is EMA-approved for low or intermediate-1 risk MDS (see text).

^bBoth originator products and biosimilars approved by the EMA have been shown to have similar safety and therapeutic equivalence in clinical practice.

^cFollow the label indications in your country.

^dLow molecular weight iron dextran.

^eThe authors suggest a dose up to 1000 mg, while drug labels might allow more.

^fIf dose is up to 1000 mg; if dose exceeds 1000 mg iron, more than 30 min is recommended, as per label.

EMA, European Medicines Agency; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; i.v., intravenous; MDS, myelodysplastic syndrome.

Iron status assessment

ID is reflected by a low transferrin saturation (TSAT < 20%) and can be further characterised as absolute ID (depleted iron stores, serum ferritin < 30 ng/mL) or functional ID (adequate iron stores

with normal or increased serum ferritin) [10]. Although investigation of bone marrow iron stores is still considered standard, circulating ferritin levels are used for distinguishing between absolute and functional ID in clinical practice. In non-inflammatory conditions, a serum ferritin level < 30 ng/mL is indicative of absolute ID,

while higher levels usually reflect appropriate iron stores. However, in cancer and other conditions with an activated inflammatory cascade, ferritin follows the path of inflammatory cytokines. Hence, the cut-off levels should be raised to 100 ng/mL in patients with inflammation or cancer. Other biological markers of ID include hypochromic, microcytic red cells, a low cellular Hb content in reticulocytes (CHR < 28 pg) and an increased percentage of hypochromic RBCs (%HYPO > 5%) as markers of both absolute and functional ID [10, 77]. Levels of soluble transferrin receptor (sTfR) and zinc protoporphyrin are increased in patients with absolute ID, but sTfR value is usually within normal limits or low in functional ID except that observed with ESA treatment [10, 78, 79]. Notably, sTfR levels can be decreased after chemotherapy [80], whereas they are increased in patients with increased erythropoietic activity (or ESA treatment) and concomitant chemotherapy, limiting the relevance of sTfR as an indicator of iron status.

Clinical evidence for treatment with i.v. iron

In controlled clinical trials investigating iron supplementation in ESA-treated anaemic cancer patients, i.v. iron supplementation (total doses in the range of 1000 mg of iron) significantly improved the haematological response to ESA treatment versus ESA alone [81–86] (Table 3). Individual studies also showed additional benefits of i.v. iron such as improvement of QoL [81] reduction of RBC transfusions [83] and ESA doses [84]. One study showed no improvement with i.v. iron and reported a higher rate of adverse events in the experimental arm with i.v. iron, but this study used an unusual (off-label) iron dosing schedule and was terminated early [87, 88]. In contrast to i.v. iron treatment, therapy with oral iron did not result in better outcomes compared with control arms with no iron at all. Conversely, the benefits of i.v. iron were substantial, with significantly greater improvement of haematological response rate than with oral iron [81, 85]. Total dose infusion of calculated iron needs was as effective as multiple low-dose infusions [81], yet, depending on the individual i.v. iron product's approved maximum infusion dose (Table 4), administration of a single 1000 mg iron dose may be more convenient for patients than multiple lower doses. Iron overload is unlikely in patients with CIA and is discussed for MDS patients.

Earlier published studies in patients with gynaecological cancer [89, 90] or with lymphoid malignancies [91] and prospective observational studies [92, 93] have shown that some patients benefit from i.v. iron even without concomitant ESA (increase in Hb concentration, reduction of RBC transfusion need), but this remains to be confirmed in larger, randomised trials. Although a trial of i.v. iron alone may be considered in individual patients with functional ID, this approach cannot be recommended based on currently available data [III, C].

With i.v. iron, no increased risk of infection or cardiovascular morbidity has been observed [81–86]. However, i.v. iron should not be given to patients with an active infection. Concomitant administration of i.v. iron and cardiotoxic chemotherapy should be avoided, and i.v. iron should either be given before or after administration of chemotherapy or at the end of a treatment cycle [III, C]. The EMA no longer recommends administration of a test dose to predict/prevent allergic reactions (mainly observed with iron dextrans [94]); however, the EMA recommends that

i.v. iron should only be administered by staff trained to evaluate and manage anaphylactic and anaphylactoid reactions and only when resuscitation facilities are immediately available. Patients should be observed closely for symptoms of hypersensitivity reactions for at least 30 min following each i.v. iron administration [95].

Is iron linked to tumour progression?

None of the trials investigating i.v. iron treatment together with ESAs showed an induction or increased progression of tumours [81–86]; however, the observation periods of these trials were rather short and there is uncertainty about potential late effects of iron treatment in cancer patients. One prospective, randomised, controlled study with longer follow-up that included treatment arms with and without i.v. iron administration in a limited number of patients with lymphoid malignancies and autologous haematopoietic stem cell transplantation showed no negative effect of i.v. iron on PFS (median follow-up 1.4 years, range of 89 days to 9.5 years) [96]. Results of available epidemiological and non-clinical studies are often conflicting and most experimental designs used intramuscular or intraperitoneal administration, high local iron concentrations and/or non-clinical iron preparations such as ferric nitrilotriacetate that do not reflect the clinical setting of iron-deficient cancer patients who receive approved i.v. iron preparations for Hb normalisation [97, 98]. When side-effects of iron are observed, they are most likely related to high loads of labile (non-transferrin-bound) iron, which catalyses the production of reactive oxygen species that lead to oxidative damage of cellular components including DNA [99, 100]. Hepatocyte iron overload with cirrhosis, as seen in hereditary haemochromatosis, has an established link to the development of hepatic cancer [101] and there seems to be a link between high dietary iron intake and colorectal cancer [102]. Notably, models that investigated iron as a potential promotor of tumour growth showed no effect of iron alone [103]. Some animal studies suggested that tumour progression occurs if large amounts of iron are given [104]; however, there is currently no clinical evidence for such an effect. This issue has not been specifically studied except in one study [96] and should be thoroughly investigated.

RBC transfusions

RBC transfusions have a long history of use with benefit to patients who present with severe anaemia symptoms or bleeding conditions and require a rapid increase in Hb and haematocrit to normal laboratory values. The literature about RBC transfusions in the cancer population is primarily derived from patients undergoing surgery. The available literature on patients receiving chemotherapy is sparse and no randomised trials have compared the value of RBC transfusions in these patients or compared the use of ESAs with RBC transfusions. Patients with non-life-threatening, cancer-related anaemia and CIA often receive RBC blood transfusions as routine treatment [105, 106], in spite of limited evidence for a significant treatment effect [107, 108] unless the underlying conditions are corrected.

Advances in molecular testing for known pathogens and potential donor-recipient incompatibilities have improved the general safety of RBC transfusions over time. Nevertheless, there remains the risk of transmitting unknown or emerging pathogens before the development and implementation of effective tests (Table 3) and an increased risk of infections due to transfusion-related immunosuppression [109]. Furthermore, stored allogeneic blood can elicit prothrombotic as well as inflammatory responses (referred to as ‘storage lesion’) [110–112]. In the oncology surgery setting, large population-based studies and a meta-analysis suggest independent associations between RBC transfusions and an increased risk of mortality, morbidity and cancer recurrence, respectively [113–116]. Meta-analyses of studies comparing restrictive versus liberal RBC transfusion thresholds, mainly in patients with orthopaedic, cardiovascular or bleeding conditions, showed significant reductions in the proportions of transfused patients and the numbers of transfused RBC units without negative impact on mortality, morbidity and functional outcome [117–120]. Analysis of studies with a restrictive Hb threshold < 7 g/dL showed significant reductions in total and in-hospital mortality, rebleeding, acute coronary syndrome, pulmonary oedema and bacterial infections with a restrictive approach, compared with a more liberal strategy [118]. Whether a higher transfusion threshold may be warranted in patients with specific conditions (e.g. acute coronary syndrome) [121] needs to be investigated. In the oncology setting, the American Society of Hematology’s Choosing Wisely® campaign and other societies’ anaemia treatment guidelines recommend transfusing only the minimum number of RBC units required to relieve severe anaemia symptoms or to return the patient to a safe Hb range (e.g. 7–8 g/dL in stable, non-cardiac in-patients) [11, 13, 122, 123].

It is recommended that RBC transfusions are reserved primarily for patients with severe anaemia symptoms in need of rapid Hb improvement [II, B]. The concept of taking every reasonable measure to increase and maintain the patient’s endogenous RBC mass early on and to protect it throughout the entire treatment, thus pre-empting transfusion, was developed in a non-oncology population and is called ‘patient blood management’ (PBM). It is based on three pillars, namely 1) optimising the patient’s own red cell mass, 2) minimising blood loss and bleeding and 3) evaluating the physiological tolerance of anaemia. It should be accompanied by a concomitant, comprehensive assessment of a patient’s haematological status at initial presentation and throughout therapy. PBM has been already well-established in the field of elective orthopaedic surgery and with the Australian National Blood Authority [124–126]. A detailed review of studies that evaluated the impact of transfusions on patient outcomes (including ischaemic events as the second leading cause of death in cancer patients [127]) is warranted but is beyond the scope of these guidelines.

Anaemia management in patients with MDS

Notably, the management of MDS-associated anaemia differs for several aspects from the above recommendations for solid tumours or other haematological malignancies such as multiple myeloma or lymphomas. In 2017 the EMA-approved ESA label of epoetin alpha (summary of product characteristics) includes treatment of some patients with MDS. Based on available data

and published predictive scores [128, 129], these anaemia treatment guidelines (Table 1 and Figure 2) and other international as well as national MDS treatment guidelines [15, 22, 130–132] have included recommendations on the use of ESAs for the management of MDS-associated anaemia, and several countries have allowed and have reimbursed ESAs in this setting. The use of investigational treatments (suggested as second-line treatment) that are currently tested in clinical trials is discussed in more detail in the ESMO Clinical Practice Guidelines for MDS [22].

Many MDS patients present with normal or even increased iron stores due to ineffective erythropoiesis plus regular RBC transfusions and require iron chelation to reduce iron overload. Other risks and limitations of RBC transfusions that are not specific to MDS are discussed in the separate section ‘RBC transfusions’ above.

Clinical evidence for use of ESAs in MDS

Three meta-analyses evaluated the efficacy of recombinant human EPO (rHuEPO) and darbepoetin in MDS patients [133–135]. The first meta-analysis (59 studies, 1936 patients) analysed controlled and single-arm studies separately [135]. In controlled trials, including mainly patients with low to intermediate-1 International Prognostic Scoring System (IPSS) risk who have been randomised to rHuEPO with or without granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF), an Hb response was reported for 27.3% of ESA-treated patients compared with 6.7% in the control groups ($P < 0.01$). In single-arm studies, pooled response rates were 32.1% for rHuEPO and 48.1% for darbepoetin alpha. Patient groups with lower endogenous EPO levels at baseline, longer treatment periods or iron supplementation showed higher Hb response rates. A second meta-analysis (30 studies, 1314 patients) that included more recent trials with higher ESAs dosing reported overall response rates of 57.6% (rHuEPO) and 59.4% (darbepoetin alpha) [133]. Three factors predicted response to rHuEPO: baseline serum EPO < 500 IU/L, French–British–American (FAB) class [either refractory anaemia (RA) or RA with excess blasts (RARS)] and fixed rather than weight-adjusted dosages. Neither of these two meta-analyses showed an increased risk of haematological or cardiovascular events or leukaemic transformation in patients receiving ESAs. No direct comparison between the different ESAs could be made. The third meta-analysis (15 studies, 741 patients) indicated equivalent erythroid response in patients treated with rHuEPO alpha alone (standard dose 30 000–40 000 IU weekly) or in combination with G-CSF or GM-CSF [134]. High-dose rHuEPO alpha monotherapy (60 000–80 000 IU weekly) resulted in significantly higher response rates compared with standard-dose treatment (64.5% versus 49.0%). Achievement of higher response rates with higher EPO doses was independent of FAB subtype or classification and transfusion dependency. So far, there is no evidence for a negative impact on survival or acute myeloid leukaemia (AML) evolution in prospective or historical controls [136–138]; however, in patients that progressed to AML, ESAs should not be used. Prospective randomised studies showed no OS benefit of ESA treatment in patients with MDS. In contrast to patients with solid tumours, there seems to be no association between the use of ESAs and thrombosis in patients with MDS [139], although this may also be related to the fact that patients with MDS only rarely receive(d) ESAs to achieve Hb levels > 12 g/dL.

Biosimilars and follow-on products

rHuEPO and recombinant G-CSF were the first biotechnological medicinal products used in haematology. More recently, follow-on products (biosimilars) of epoetin have been granted marketing authorisation by the EMA [140, 141]. A biosimilar is a biological medicinal product (a medicine produced by or derived from a biological source) that is similar to another biological medicinal product that has already been authorised for use in Europe [142]. Biological medicinal products similar to a reference medicinal product do not usually meet all the conditions to be considered as a generic medicinal product, mainly due to manufacturing process characteristics, raw materials used and molecular characteristics. Authorisation of a biosimilar requires studies showing that the product is similar to the reference medicine and does not have any meaningful differences from the reference medicine in terms of quality, safety or efficacy, yet the amount of information on safety and efficacy required is usually less than the amount required to authorise an original biological medicinal product [143].

Notably, only products that are approved, produced and distributed according to a strict biosimilar guidance of a regulatory authority such as the EMA or the Food and Drug Administration (FDA) should be considered as biosimilar and be differentiated from products that are not manufactured and quality-controlled in compliance with the biosimilar guidance or even counterfeit medicines. Use of epoetin products that have not been approved by the EMA has been linked to an increased incidence of antibody-mediated pure red cell aplasia (PRCA). Among 30 patients with renal insufficiency who experienced a sudden loss of response after the switch from an epoetin originator, 23 were positive for antibodies to rHuEPO and all of them had PRCA, compared with none in the seven antibody-negative patients [144]. Whether this increased rate of antibody-mediated PRCA cases is actually related to quality-controlled non-originator products or an increased background of idiopathic PRCA in the population [145] or an elevated content of protein aggregates in counterfeit or smuggled products with interrupted cold chain (2–8 °C) [146] cannot be clarified.

Head-to-head trials and long-term follow-up with biosimilars of epoetin that were manufactured and distributed according to established and regularly updated biosimilar guidelines like the scientific guidelines on biosimilar medicines issued by EMA have shown the safety and therapeutic equivalence of biosimilars and originator products in patients with renal insufficiency [147–150] and oncology patients [151]. The effectiveness of a biosimilar epoetin has also been shown for patients with CIA in clinical practice [152].

Independently of which epoetin has been used to initiate treatment, switching preparations in responsive and stable patients should be avoided [153] to prevent issues of immunogenicity and confused pharmacovigilance reports [V, C]. Automatic substitution should be only allowed in drug-naïve patients and if the clinician accepts a therapeutic equivalence [153]. Furthermore, reliable monitoring of treatment outcomes with biosimilars is crucial to substantially increase the numbers of recorded patient-years under treatment above those requested for regulatory approval; another reason why the use of different preparations within one patient should be avoided.

Regulatory evaluation of i.v. iron follow-on products is currently determined by the pathway for generic medicinal products. However, there is growing clinical [154–157] and non-clinical [158] evidence raising doubts about the interchangeability and/or substitutability of these complex drugs [159]. Concerns regarding the regulatory assessment of nanoparticle iron follow-on products are also highlighted by the EMA in a reflection paper on non-clinical and clinical data requirements [160]. Accordingly, new regulatory approaches that focus more on comparability of clinical safety and therapeutic efficacy are required (and are emerging) for the approval of follow-on products of such non-biological complex drugs [161, 162]. As for biosimilars, switching preparations in adequately treated patients and automatic substitution should be avoided [V, C].

Conclusions

The largest amount of evidence in the treatment of symptomatic CIA is available for ESAs. ESAs are relatively safe except for an increased risk of VTE and development of PRCA in very rare cases. Outside approved indications, ESAs have been linked with increased mortality.

i.v. iron has been shown to significantly enhance the activity of ESAs, but long-term results are not available. As a sole therapy, i.v. iron improves anaemia in cancer patients with ID, but representative, randomised studies and long-term data are lacking.

Opposite the large number of ESA studies in cancer patients, no randomised trials have investigated the use of RBC transfusions in this population. Based on findings from studies in non-oncology populations and cancer patients undergoing surgery, it is recommended that RBC transfusions are reserved for patients with Hb levels below 7–8 g/dL and situations when rapid improvement of severely symptomatic anaemia is required [II, B].

MDS patients with low to intermediate-1 risk (IPSS) or very low to intermediate risk (revised; IPSS-R) disease and symptomatic anaemia should be considered for ESA therapy, despite the fact that not all ESAs are currently EMA-approved for use in patients with MDS [I, A].

The FDA recently determined that the ESA Risk Evaluation and Mitigation Strategy (related to the use of ESAs to treat patients with anaemia due to associated myelosuppressive chemotherapy) was no longer necessary to ensure that the benefits outweigh the risks of shortened OS and/or increased risk of tumour progression or recurrence in patients with cancer [163]. In addition, the FDA's Oncology Drugs Advisory Committee has recently recommended approval of a biosimilar to epoetin alpha [164].

In Europe, recently published German guidelines have reached similar conclusions about the adequate safety and appropriate use of ESAs [165].

Personalised medicine

Although these guidelines take into account the Hb, vitamin and iron levels of patients before treatment is applied, personalised medicine requires an individualised approach. Further research is needed on potential markers to determine the best chances of

Table 5. Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America–United States Public Health Service Grading System^a)**Levels of evidence**

- I Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomised trials without heterogeneity
- II Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity
- III Prospective cohort studies
- IV Retrospective cohort studies or case–control studies
- V Studies without control group, case reports, expert opinions

Grades of recommendation

- A Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
- B Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
- C Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, . . .), optional
- D Moderate evidence against efficacy or for adverse outcome, generally not recommended
- E Strong evidence against efficacy or for adverse outcome, never recommended

^aBy permission of the Infectious Diseases Society of America [23].

response to the applied agents, in particular to iron and epoetins. Ongoing studies on hepcidin might provide an insight for better use of i.v. iron.

Follow-up, long-term implications and survivorship

Long-term data on both the safety and OS data of i.v. iron in the setting of cancer patients are not currently available. Other issues are described and discussed in the above text.

Methodology

Since the last European anaemia treatment guidelines were published (ESMO in 2010, EORTC in 2007), new data about treatment options for cancer-related anaemia and CIA have become available. In addition, treatment options for anaemia in patients with MDS of IPSS and/or IPSS-R lower risk have been evaluated. The authors conducted electronic searches of the Medline database for English language records from 2007 to March 2015 (search terms: cancer, tumour, haematological malignancy, MDS, chemotherapy, anaemia, erythropoiesis, iron, vitamin, folate, deficiency and combinations thereof) and manually searched abstract books of the major international oncology congresses. The authors met in March 2013, 2014 and 2015 to discuss the findings and agreed on a consensus for the guidelines in several meetings and phone conferences and reviewed the manuscript during 2016–2017. These Clinical Practice Guidelines were developed in accordance with the ESMO standard operating procedures for Clinical Practice Guidelines development (<http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology>).

The relevant literature has been selected by the expert authors. Levels of evidence and grades of recommendation have been applied using the system shown in Table 5. Statements without grading were considered justified standard clinical practice by the

experts and the ESMO Faculty. This manuscript has been subjected to an anonymous peer review process.

Acknowledgements

This work was initiated by a working party started by the EORTC and finished in agreement with ESMO given the task of updating the guidelines on the use of ESAs in anaemic patients with cancer. Medical writing support was provided by Walter Fürst, SFL Regulatory Affairs & Scientific Communication and paid by funds from the Clinique de Genolier Cancer Centre. Working party meetings were held during an annual European Accreditation Council for Continuing Medical Education-accredited meeting on anaemia and neutropaenia organised by the agency Vision Plus.

Disclosure

MA has received grants or speaker honoraria from or serves on an advisory board and speaker's bureau for Amgen, Hexal, F. Hoffmann-La Roche, Hospira, Sanofi-Aventis, Sandoz and Vifor Pharma. YB has received research grants, consulting fees or speaker honoraria from Amgen, F. Hoffmann-La Roche and Vifor Pharma. CB has received speaker honoraria, research grants or consulting fees from Amgen, Janssen Cilag, Hexal and F. Hoffmann-La Roche and has served on advisory boards for Amgen, F. Hoffmann-La Roche and Vifor Pharma. MD has acted as a consultant to Janssen-Cilag. PG has received speaker honoraria from Vifor Pharma. JG's institution has received payments from Amgen to support clinical trials. AH has served as a consultant or advisor for and/or has received speaker's honoraria from the Australian Red Cross Services, B Braun Melsungen, Ethicon Biosurgery, Hospira, Vifor Pharma and the Western Australia Department of Health. HL has received research grants or speaker honoraria from Amgen, F. Hoffman-La Roche, Janssen Cilag, Novartis, Teva and Vifor Pharma. TL has not

received honoraria from any company within the last 3 years but previously received honoraria from Amgen, F. Hoffman-La Roche, Janssen Cilag and Vifor Pharma. HL has received consulting fees or speaker honoraria from F. Hoffman-La Roche and Vifor Pharma. AO has received research grants or speaker honoraria from Amgen, F. Hoffmann-La Roche and Vifor Pharma. PP has received honoraria from Amgen and Janssen Cilag. VS has received honoraria from Celgene, Janssen Cilag, Novartis and Onconova Therapeutics. DS served as consultant or advisor for Janssen Cilag. RS has received research grants and honoraria from Celgene, Janssen-Cilag Novartis and Teva and has served as scientific advisor for Celgene. KJ has reported honoraria from Amgen, Merck, MSD, Helsinn, Tesaro and Hexal and being a member of the advisory board of Merck, MSD, Helsinn and Tesaro. JH has declared no conflicts of interest.

References

- Ludwig H, Van Belle S, Barrett-Lee P. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. *Eur J Cancer* 2004; 40: 2293–2306.
- Ludwig H, Muldur E, Endler G, Hubl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. *Ann Oncol* 2013; 24: 1886–1892.
- Delarue R, Tilly H, Salles GA et al. Iron parameters and relation to prognosis in elderly patients with aggressive lymphoma receiving first line immunochemotherapy: an analysis of the Lysa LNH 03-6B Study. *Blood* 2013; 122 (Abstr 2202).
- Anker SD, Comin Colet J, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med* 2009; 361: 2436–2448.
- Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. *Ann Oncol* 2004; 15: 979–986.
- Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. *Cancer* 2002; 95: 888–895.
- Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. *Br J Cancer* 2001; 84(Suppl 1): 31–37.
- Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. *Cancer* 2001; 91: 2214–2221.
- Hudis CA, Van Belle S, Chang J, Muenstedt K. rHuEPO and treatment outcomes: the clinical experience. *Oncologist* 2004; 9(Suppl 5): 55–69.
- Aapro M, Österborg A, Gascón P et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of intravenous iron. *Ann Oncol* 2012; 23: 1954–1962.
- National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology; Cancer and Chemotherapy-Induced Anemia – v.1.2018, 2017; http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf (18 October 2017, date last accessed).
- Aapro M, Chernov VM, Gladkov OA et al. Practical recommendations for the treatment of anemia in cancer patients. *Malignant Tumors* 2016; 4(Special Issue 2): 368–377.
- Rizzo JD, Brouwers M, Hurley P et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. *Blood* 2010; 116: 4045–4059.
- Santini V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. *Oncologist* 2011; 16(Suppl 3): 35–42.
- Malcovati L, Hellström-Lindberg E, Bowen D et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. *Blood* 2013; 122: 2943–2964.
- Efficace F, Gaidano G, Breccia M et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. *Br J Haematol* 2015; 168: 361–370.
- de Swart L, Smith A, Johnston TW et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. *Br J Haematol* 2015; 170: 372–383.
- Schrijvers D, De Samblanx H, Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. *Ann Oncol* 2010; 21(Suppl 5): v244–v247.
- Bokemeyer C, Aapro M, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. *Eur J Cancer* 2007; 43: 258–270.
- Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. *Oncologist* 2008; 13(Suppl 3): 33–36.
- Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. *Br J Cancer* 2012; 106: 1249–1258.
- Fenaux P, Haase D, Sanz GF et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25(Suppl 3): iii57–iii69.
- Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among haematopoietic stem cell transplant recipients. *Clin Infect Dis* 2001; 33: 139–144.
- Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. *J Clin Oncol* 2001; 19: 2875–2882.
- Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. *Br J Haematol* 2003; 122: 394–403.
- Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. *J Clin Oncol* 2001; 19: 2865–2874.
- Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. *J Natl Cancer Inst* 2002; 94: 1211–1220.
- Aapro M. An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology. *Oncologist* 2009; 14(Suppl 1): 1–5.
- Tonia T, Mettler A, Robert N et al. Erythropoietin or darbepoetin for patients with cancer. *Cochrane Database Syst Rev* 2012; 12: CD003407.
- Bohlius J, Tonia T, Nüesch E et al. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analysis of published and unpublished data. *Br J Cancer* 2014; 111: 33–45.
- Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. *Blood* 1995; 86: 4446–4453.
- Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. *JAMA* 2008; 299: 914–924.

33. Bohlius J, Schmidlin K, Brillant C et al. Erythropoietin or darbepoetin for patients with cancer—meta-analysis based on individual patient data. *Cochrane Database Syst Rev* 2009; 3: CD007303.
34. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. *Lancet* 2003; 362: 1255–1260.
35. Hoff CM, Hansen HS, Overgaard M et al. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy—results from the randomized DAHANCA 5 study. *Radiother Oncol* 2011; 98: 28–33.
36. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. *J Clin Oncol* 2005; 23: 5960–5972.
37. Smith RE Jr, Aapro MS, Ludwig H et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. *J Clin Oncol* 2008; 26: 1040–1050.
38. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. *J Clin Oncol* 2007; 25: 1027–1032.
39. Leyland-Jones B, Bondarenko I, Nemsadze G et al. A randomized, open-label, multicenter, phase III study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy. *J Clin Oncol* 2016; 34: 1197–1207.
40. Engert A, Josting A, Haverkamp H et al. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. *J Clin Oncol* 2010; 28: 2239–2245.
41. Moebus V, Jackisch C, Schneeweiss A et al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. *J Nat Cancer Inst* 2013; 105: 1018–1026.
42. Pirker R, Ramlau RA, Schuette W et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. *J Clin Oncol* 2008; 26: 2342–2349.
43. Aapro M, Osterwalder B, Scherhag A, Burger HU. Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. *Br J Cancer* 2009; 101: 1961–1971.
44. Aapro M, Moebus V, Nitz U et al. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis. *Ann Oncol* 2015; 26: 688–695.
45. Glaspy J, Crawford J, Vansteenkiste J et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. *Br J Cancer* 2010; 102: 301–315.
46. Ludwig H, Crawford J, Osterborg A et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. *J Clin Oncol* 2009; 27: 2838–2847.
47. Vansteenkiste J, Glaspy J, Henry D et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. *Lung Cancer* 2012; 76: 478–485.
48. Hershman DL, Buono DL, Malin J et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. *J Natl Cancer Inst* 2009; 101: 1633–1641.
49. National Institute for Health and Care Excellence (NICE). 2014. Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142). www.nice.org.uk/guidance/ta323 (23 February 2015, date last accessed).
50. Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? *J Clin Oncol* 2006; 24: 4708–4713.
51. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. *Crit Rev Oncol Hematol* 2008; 67: 39–61.
52. Sinclair AM, Todd MD, Forsythe K et al. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. *Cancer* 2007; 110: 477–488.
53. Acs G, Acs P, Beckwith SM et al. Erythropoietin and erythropoietin receptor expression in human cancer. *Cancer Res* 2001; 61: 3561–3565.
54. Swift S, Ellison AR, Kassner P et al. Absence of functional EpoR expression in human tumor cell lines. *Blood* 2010; 115: 4254–4263.
55. Brown WM, Maxwell P, Graham AN et al. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. *Stem Cells* 2007; 25: 718–722.
56. Elliott S, Busse L, Bass MB et al. Anti-epo receptor antibodies do not predict epo receptor expression. *Blood* 2006; 107: 1892–1895.
57. Elliott S, Busse L, McCaffery I et al. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. *J Immunol Methods* 2010; 352: 126–139.
58. Elliott S, Swift S, Busse L et al. Epo receptors are not detectable in primary human tumor tissue samples. *PLoS One* 2013; 8: e68083.
59. Elliott S, Sinclair A, Collins H et al. Progress in detecting cell-surface protein receptors: the erythropoietin receptor example. *Ann Hematol* 2014; 93: 181–192.
60. Liang K, Esteva FJ, Albarracin C et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. *Cancer Cell* 2010; 18: 423–435.
61. Cao Y, Lathia JD, Eyles CE et al. Erythropoietin receptor signaling through stat3 is required for glioma stem cell maintenance. *Genes Cancer* 2010; 1: 50–61.
62. Kumar SM, Zhang G, Bastian BC et al. Erythropoietin receptor contributes to melanoma cell survival in vivo. *Oncogene* 2012; 31: 1649–1660.
63. Wu P, Zhang N, Wang X et al. The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells. *PLoS One* 2012; 7: e45122.
64. Osterborg A, Aapro M, Cornes P et al. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. *Eur J Cancer* 2007; 43: 510–519.
65. Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. *Thromb Res* 2009; 123: 679–686.
66. Zonder JA. Thrombotic complications of myeloma therapy. *Hematology Am Soc Hematol Educ Program* 2006: 348–355.
67. Galli M, Elice F, Crippa C et al. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. *Haematologica* 2004; 89: 1141–1142.
68. Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. *N Engl J Med* 2006; 354: 2079–2080.
69. Mandalà M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. *Ann Oncol* 2011; 22(Suppl 6): vi85–vi92.
70. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology; Cancer-Associated Venous Thromboembolic Disease – v.1.2017, 2017; http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf (18 October 2017, date last accessed).
71. Lyman GH, Bohlke K, Khorana AA et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. *J Clin Oncol* 2015; 33: 654–656.
72. Henry DH, Dahl NV, Auerbach MA. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. *Am J Hematol* 2012; 87: 308–310.

73. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. *Cancer* 2005; 104: 2822–2929.
74. Evstatiev R, Gasche C. Iron sensing and signalling. *Gut* 2012; 61: 933–952.
75. Brugnara C, Chambers LA, Malynn E et al. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. *Blood* 1993; 81: 956–964.
76. Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med* 2005; 352: 1011–1023.
77. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. *Clin J Am Soc Nephrol* 2006; 1(Suppl 1): S4–S8.
78. Steinmetz HT, Tsalamoukas A, Schmitz S et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. *Support Care Cancer* 2010; 19: 261–269.
79. Hastka J, Lasserre JJ, Schwarzbeck A, Hehlmann R. Central role of zinc protoporphyrin in staging iron deficiency. *Clin Chem* 1994; 40: 768–773.
80. Xu Q, Zhu M, Yang T et al. Quantitative assessment of human serum transferrin receptor in breast cancer patients pre- and post-chemotherapy using peptide immunoaffinity enrichment coupled with targeted proteomics. *Clin Chim Acta* 2015; 448: 118–123.
81. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. *J Clin Oncol* 2004; 22: 1301–1307.
82. Auerbach M, Silberstein PT, Webb RT et al. Darbepoetin alfa 300 or 500 µg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. *Am J Hematol* 2010; 85: 655–663.
83. Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. *J Clin Oncol* 2008; 26: 1611–1618.
84. Hedenus M, Birgegård G, Nasmän P et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. *Leukemia* 2007; 21: 627–632.
85. Henry DH, Dahl NV, Auerbach M et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. *Oncologist* 2007; 12: 231–242.
86. Pedrazzoli P, Farris A, Del Prete S et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. *J Clin Oncol* 2008; 26: 1619–1625.
87. Aapro M, Beguin Y, Birgegård G et al. Too-low iron doses and too many dropouts in negative iron trial? *J Clin Oncol* 2011; 29: e525–e526.
88. Steensma DP, Sloan JA, Dakhil SR et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. *J Clin Oncol* 2011; 29: 97–105.
89. Dangsuan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. *Gynecol Oncol* 2010; 116: 522–525.
90. Kim YT, Kim SW, Yoon BS et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. *Gynecol Oncol* 2007; 105: 199–204.
91. Hedenus M, Karlsson T, Ludwig H et al. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. *Med Oncol* 2014; 31: 302.
92. Steinmetz T, Tschenechne B, Harlin O et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. *Ann Oncol* 2013; 24: 475–482.
93. Toledano A, Luporsi E, Morere JF et al. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. *Support Care Cancer* 2016; 24: 67–75.
94. Bailie GR, Hörl WH, Verhoef JJ. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. *Arzneimittelforschung* 2011; 61: 267–275.
95. European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines 2013; http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144874.pdf (22 February 2015, date last accessed).
96. Jaspers A, Baron F, Maertens J et al. Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation. *Am J Hematol* 2015; 90: e133–e134.
97. Beguin Y, Aapro M, Ludwig H et al. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis—a critical review. *Crit Rev Oncol Hematol* 2014; 89: 1–15.
98. Torti SV, Torti FM. Iron and cancer: more ore to be mined. *Nat Rev Cancer* 2013; 13: 342–355.
99. Kohgo Y, Ikuta K, Ohtake T et al. Body iron metabolism and pathophysiology of iron overload. *Int J Hematol* 2008; 88: 7–15.
100. Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. *Mutat Res* 2003; 531: 81–92.
101. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. *Gastroenterology* 2004; 127(5 Suppl 1): S79–S86.
102. Nelson RL. Iron and colorectal cancer risk: human studies. *Nutr Rev* 2001; 59: 140–148.
103. Rezazadeh H, Nayebi AR, Garjani A et al. Evidence that iron overload plus croton oil induce skin tumours in mice. *Hum Exp Toxicol* 2005; 24: 409–413.
104. Bergeron RJ, Streiff RR, Elliott GT. Influence of iron on in vivo proliferation and lethality of L1210 cells. *J Nutr* 1985; 115: 369–374.
105. Link H, Schmitz S. Treatment of cancer-associated anaemia: results from a two-day cross-sectional survey in Germany. *Onkologie* 2013; 36: 266–272.
106. Ludwig H, Aapro M, Bokemeyer C et al. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. *Support Care Cancer* 2014; 22: 2197–2206.
107. Osterborg A. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? *Med Oncol* 1998; 15(Suppl 1): S47–S49.
108. Schrijvers D. Management of anemia in cancer patients: transfusions. *Oncologist* 2011; 16(Suppl 3): 12–18.
109. Murphy GJ, Reeves BC, Rogers CA et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. *Circulation* 2007; 116: 2544–2552.
110. Isbister JP, Shander A, Spahn DR et al. Adverse blood transfusion outcomes: establishing causation. *Transfus Med Rev* 2011; 25: 89–101.
111. Baek JH, D’Agnillo F, Vallelian F et al. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. *J Clin Invest* 2012; 122: 1444–1458.
112. Upile T, Jerjes W, Mahil J et al. Blood product transfusion and cancer prognosis. *Clin Adv Hematol Oncol* 2009; 7: 656–661.
113. Al-Refaie WB, Parsons HM, Markin A et al. Blood transfusion and cancer surgery outcomes: a continued reason for concern. *Surgery* 2012; 152: 344–354.
114. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. *Cochrane Database Syst Rev* 2006; 1: CD005033.
115. Bakkum-Gamez JN, Dowdy SC, Borah BJ et al. Predictors and costs of surgical site infections in patients with endometrial cancer. *Gynecol Oncol* 2013; 130: 100–106.
116. Halabi WJ, Jafari MD, Nguyen VQ et al. Blood transfusions in colorectal cancer surgery: incidence, outcomes, and predictive factors: an

- American College of Surgeons National Surgical Quality Improvement Program analysis. *Am J Surg* 2013; 206: 1024–1032.
117. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev* 2012; 4: CD002042.
 118. Salpeter SR, Buckley JS, Chatterjee S. Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review. *Am J Med* 2014; 127: 124–131.
 119. Rohde JM, Dimcheff DE, Blumberg N et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. *JAMA* 2014; 311: 1317–1326.
 120. Holst LB, Petersen MW, Haase N et al. Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. *BMJ* 2015; 350: h1354.
 121. Carson JL, Hebert PC. Should we universally adopt a restrictive approach to blood transfusion? It's all about the number. *Am J Med* 2014; 127: 103–104.
 122. Callum JL, Waters JH, Shaz BH et al. The AABB recommendations for the choosing wisely campaign of the American Board of Internal Medicine. *Transfusion* 2014; 54: 2344–2352.
 123. Hicks LK, Bering H, Carson KR et al. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. *Blood* 2013; 122: 3879–3883.
 124. Goodnough LT, Maniatis A, Earnshaw P et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. *Br J Anaesth* 2011; 106: 13–22.
 125. Hofmann A, Farmer S, Shander A. Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management. *Oncologist* 2011; 16(Suppl 3): 3–11.
 126. Goodnough LT, Shander A. Current status of pharmacologic therapies in patient blood management. *Anesth Analg* 2013; 116: 15–34.
 127. Sanon S, Lenihan DJ, Mouhayar E. Peripheral arterial ischemic events in cancer patients. *Vasc Med* 2011; 16: 119–130.
 128. Hellström-Lindberg E, Gulbrandsen N, Lindberg G et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. *Br J Haematol* 2003; 120: 1037–1046.
 129. Santini V, Schemenau J, Levis A et al. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? *Blood* 2013; 122: 2286–2288.
 130. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology; Myelodysplastic Syndromes – v.1.2018, 2017; http://www.nccn.org/professionals/physician_gls/pdf/mds.pdf (18 October 2017, date last accessed).
 131. Stauder R, Wimazal F, Nösslinger T et al. Individualized management and therapy of myelodysplastic syndromes. *Wien Klin Wochenschr* 2008; 120: 523–537.
 132. Santini V, Alessandrino PE, Angelucci E et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. *Leuk Res* 2010; 34: 1576–1588.
 133. Moyo V, Lefebvre P, Duh MS et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. *Ann Hematol* 2008; 87: 527–536.
 134. Mundle S, Lefebvre P, Vekeman F et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. *Cancer* 2009; 115: 706–715.
 135. Ross SD, Allen IE, Probst CA et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. *Oncologist* 2007; 12: 1264–1273.
 136. Greenberg PL, Sun Z, Miller KB et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). *Blood* 2009; 114: 2393–2400.
 137. Jädersten M, Malcovati L, Dybedal I et al. Erythropoietin and granulocyte colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. *J Clin Oncol* 2008; 26: 3607–3613.
 138. Park S, Grabar S, Kelaidi C et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. *Blood* 2008; 111: 574–582.
 139. Smith SW, Sato M, Gore SD et al. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. *Haematologica* 2012; 97: 15–20.
 140. Weise M, Bielsky MC, De Smet K et al. Biosimilars: what clinicians should know. *Blood* 2012; 120: 5111–5117.
 141. Weise M, Kurki P, Wolff-Holz E et al. Biosimilars: the science of extrapolation. *Blood* 2014; 124: 3191–3196.
 142. European Medicines Agency. Biosimilar medicines 2013; http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000318.jsp (28 February 2015, date last accessed).
 143. Brinks V, Hawe A, Basmeleh AH et al. Quality of original and biosimilar epoetin products. *Pharm Res* 2011; 28: 386–393.
 144. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. *Kidney Int* 2011; 80: 88–92.
 145. Ferro HH, González EB. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. *Kidney Int* 2012; 81: 1273–1274.
 146. Fotiou F, Aravind S, Wang PP et al. Impact of illegal trade on the quality of epoetin alfa in Thailand. *Clin Ther* 2009; 31: 336–346.
 147. Wizemann V, Rutkowski B, Baldamus C et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. *Curr Med Res Opin* 2008; 24: 625–637.
 148. Krivoshiev S, Todorov VV, Manitius J et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. *Curr Med Res Opin* 2008; 24: 1407–1415.
 149. Baldamus C, Krivoshiev S, Wolf-Pflugmann M et al. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. *Adv Ther* 2008; 25: 1215–1228.
 150. Haag-Weber M, Vetter A, Thyroff-Friesinger U. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. *Clin Nephrol* 2009; 72: 380–390.
 151. Weigang-Köhler K, Vetter A, Thyroff-Friesinger U. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. *Oncol Res Treat* 2009; 32: 168–174.
 152. Kerkhofs L, Boschetti G, Lugini A et al. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience. *Future Oncol* 2012; 8: 751–756.
 153. Barosi G, Bosi A, Abbraccio MP et al. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. *Haematologica* 2011; 96: 937–942.
 154. Lee ES, Park BR, Kim JS et al. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. *Curr Med Res Opin* 2013; 29: 141–147.
 155. Martin-Malo A, Merino A, Carracedo J et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. *Nephrol Dial Transplant* 2012; 27: 2465–2471.
 156. Rottembourg J, Kadri A, Leonard E et al. Do two intravenous iron sucrose preparations have the same efficacy? *Nephrol Dial Transplant* 2011; 26: 3262–3267.
 157. Stein J, Dignass A, Chow KU. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. *Curr Med Res Opin* 2012; 28: 241–243.

158. Toblli JE, Cao G, Oliveri L, Angerosa M. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. *Inflamm Allergy Drug Targets* 2012; 11: 66–78.
159. Borchard G, Flühmann B, Mühlebach S. Nanoparticle iron medicinal products - requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies. *Regul Toxicol Pharmacol* 2012; 64: 324–328.
160. European Medicines Agency. Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product 2015; http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500184922 (30 March 2015, date last accessed).
161. Ehmann F, Sakai-Kato K, Duncan R et al. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. *Nanomedicine (Lond)* 2013; 8: 849–856.
162. Schellekens H, Stegemann S, Weinstein V et al. How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider. *AAPS J* 2014; 16: 15–21.
163. U.S. Food & Drug Administration. Information on erythropoiesis-stimulating agents (ESA) epoetin alfa (marketed as Procrit, Epogen), darbepoetin alfa (marketed as Aranesp), 13 April 2017; <https://www.fda.gov/Drugs/DrugSafety/ucm109375.htm> (15 June 2017, date last accessed).
164. US Food & Drug Administration. FDA ODAC Briefing Document: BLA125545 “Epoetin Hospira”, a proposed biosimilar to Epogen/Procrit (epoetin alfa), 25 May 2017; <https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM559967.pdf> (15 June 2017, date last accessed).
165. Jordan K, Feyer P, Höller U et al. Clinical practice guideline: supportive treatments for patients with cancer. *Dtsch Arztebl Int* 2017; 114: 481–487.